PeCan-Seq enables sensitive, non-invasive ctDNA analysis for pediatric cancers, with high accuracy for hematologic ...

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung ...

is an advanced stage of prostate cancer High ctDNA% identifies aggressive mCRPC A new tool simplifies ctDNA testing, ensuring timely and accurate prostate cancer management Prostate cancer is the ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

Cancer, one of the most life-threatening diseases, is projected to affect over 35 million people worldwide in 2050 — 77% more ...

The evolution of pancreatic cancer screening technologies is pivotal for early detection, addressing key challenges to ...

The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...

The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients. "Our presence at AMP 2024 underscores ...